ClinicalTrials.gg
CompletedNCT05896527IlluminateUpdated Apr 4, 2025Results posted

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of DC-806 and Placebo in Plaque Psoriasis, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Completed at 56 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
229
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.

Enrollment
12th of 36
229 · median 181
Started
2023
with 1 other
Phase 2
9 of 36
none open now
Registered
31st of 36
by date

Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 12th largest by enrollment, is one of 2 that started in 2023, is one of 9 in phase 2, and was the 31st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Psoriasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

This was a 12-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis. This study evaluated the efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple oral doses of DC-806 in participants with moderate to severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female, 18 to 70 years of age
  • (BMI) of 18 to 40 kg/m2
  • All of the following psoriasis criteria:

    • Clinical diagnosis of plaque psoriasis for ≥6 months before the Baseline visit
    • Stable moderate to severe chronic plaque psoriasis, defined as ≥10% BSA psoriasis involvement, sPGA score of ≥3, and PASI score ≥12 at the Screening and Baseline visits
    • Candidate for phototherapy or systemic therapy, as assessed by the Investigator
  • Women of (WOCBP) and men who are sexually active with WOCBP must be willing to use a highly effective method of during the study and for ≥30 days after the last dose of study drug
  • Willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study drug

Key Exclusion Criteria:

  • Have had a flare of psoriasis during the 12 weeks before the Baseline visit, as assessed by the Investigator
  • History of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, medication-induced or medication-exacerbated psoriasis
  • History of chronic infections including (HIV) or viral hepatitis ( virus [HBV], virus [HCV])
  • History of active tuberculosis (TB)
  • History or evidence of active infection (including but not limited to coronavirus disease 2019 [COVID-19] infection) and/or febrile illness within 7 days, serious infections leading to hospitalization and intravenous antibiotic treatment within 90 days, or serious infection requiring antibiotic treatment within 30 days before the first dose of study drug
  • History of or lymphoproliferative disease except resected cutaneous squamous cell or basal cell carcinoma that has been treated without recurrence
  • Presence of active suicidal ideation, or positive suicide behavior using the "Baseline/Screening" version of the Columbia Suicide Severity Rating Scale (C-SSRS) and with either of the following criteria:

    • History of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt) within 5 years before the Screening visit
    • Suicidal ideation in the past month before the Screening visit as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the "Baseline/Screening" version of the C-SSRS
  • Participant has experienced primary failure (no response at approved doses after ≥3 months of therapy) to one or more therapeutic agents targeted to IL-17 (including but not limited to secukinumab, ixekizumab, brodalumab, bimekizumab)
  • Systemic use of known strong and moderate cytochrome P450 (CYP)3A4 inhibitors or strong inducers from Screening through the end of the study
  • A 12-lead (ECG) at Screening that demonstrates clinically significant abnormalities or criteria associated with abnormalities including prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) (>500 msec)
  • Laboratory values meeting the following criteria within the screening period before the first dose of study drug:

    • Serum ≥2× (ULN)
    • Serum alanine transaminase ≥2×ULN
    • Serum total, direct, or indirect ≥2.0 mg/dL; except for participants with isolated elevation of indirect bilirubin relating to a confirmed diagnosis of Gilbert syndrome
    • Estimated (GFR) by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula \<45 mL/min/1.73m2
    • Total white blood cell count \<3000/μL
    • \<1500/μL
    • count \<100,000/μL
    • \<9 g/dL
  • In the opinion of the Investigator or Sponsor, have any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the participant's enrollment in the study
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
229 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo tablets orally twice daily (BID) for 12 weeks.

    Other: Placebo

  • Experimental
    DC-806 200 mg BID

    Participants received 200 milligrams (mg) of DC-806 tablets orally twice daily for 12 weeks.

    Drug: DC-806

  • Experimental
    DC-806 400 mg BID

    Participants received 400 mg of DC-806 tablets orally twice daily for 12 weeks.

    Drug: DC-806

  • Experimental
    DC-806 600 mg QD

    Participants received 600 mg of DC-806 tablets orally once daily (QD) for 12 weeks.

    Drug: DC-806

  • Experimental
    DC-806 800 mg BID

    Participants received 800 mg of DC-806 tablets orally twice daily for 12 weeks.

    Drug: DC-806

Interventions

  • DrugDC-806

    DC-806 was supplied as tablets to be administered orally.

  • OtherPlacebo

    Matching placebo was supplied as tablets to be administered orally.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12

    Participants achieving a PASI-75 without the use of other background antipsoriasis therapy were considered responders. The PASI quantifies the severity of a psoriasis based on lesion severity and the percent of body surface area (BSA) affected. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region, and then multiplied by a constant corresponding to the region's percent BSA (0.1, 0.3, 0.2, and 0.4 for the above 4 regions, respectively). The resultant score for each anatomic region is then summed to yield the final PASI score. It ranges from 0 to 72, with higher scores reflecting greater disease severity.

    Time frame: Week 12

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEASs Leading to Treatment Discontinuations

    * A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug. * An SAE is any untoward medical occurrence that results in 1 of the following: death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent 1 of the other outcomes listed in the definition above.

    Time frame: Baseline through End of follow-up (Up to 16 weeks)

07

Results

Posted Apr 4, 2025

Participant flow

Participant flow — Overall Study
MilestonePlaceboDC-806 200 mg BIDDC-806 400 mg BIDDC-806 600 mg QDDC-806 800 mg BID
Started4445464747
Received at least one dose of the study drug4444464747
Safety analysis set4344464847
Completed3231404044
Not completed1214673
Withdrew: Withdrawal by subject1110432
Withdrew: Lost to follow-up02221
Withdrew: Significant protocol noncompliance01000
Withdrew: Eligibility criteria not met10000
Withdrew: Sponsor's decision00010
Withdrew: Investigator's decision01000
Withdrew: Pregnancy of his partner00010

Outcome measures

PrimaryPercentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12

Participants achieving a PASI-75 without the use of other background antipsoriasis therapy were considered responders. The PASI quantifies the severity of a psoriasis based on lesion severity and the percent of body surface area (BSA) affected. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region, and then multiplied by a constant corresponding to the region's percent BSA (0.1, 0.3, 0.2, and 0.4 for the above 4 regions, respectively). The resultant score for each anatomic region is then summed to yield the final PASI score. It ranges from 0 to 72, with higher scores reflecting greater disease severity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12
percentage of participantsPlaceboDC-806 200 mg BIDDC-806 400 mg BIDDC-806 600 mg QDDC-806 800 mg BID
Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 1213.66.821.71736.2
Statistical analysis
  • Placebo vs DC-806 200 mg BID · Fisher Exact · p = 0.4839 · Odds ratio (or): 0.46 · 95% CI 0.07 to 2.37DC-806 200 mg BID compared to Placebo
  • Placebo vs DC-806 400 mg BID · Fisher Exact · p = 0.4111 · Odds ratio (or): 1.76 · 95% CI 0.51 to 6.49DC-806 400 mg BID compared to Placebo
  • Placebo vs DC-806 600 mg QD · Fisher Exact · p = 0.7744 · Odds ratio (or): 1.30 · 95% CI 0.36 to 4.99DC-806 600 mg QD compared to Placebo
  • Placebo vs DC-806 800 mg BID · Fisher Exact · p = 0.0164 · Odds ratio (or): 3.59 · 95% CI 1.15 to 12.37DC-806 800 mg BID compared to Placebo
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEASs Leading to Treatment Discontinuations

* A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug. * An SAE is any untoward medical occurrence that results in 1 of the following: death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent 1 of the other outcomes listed in the definition above.

Time frame:
Baseline through End of follow-up (Up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEASs Leading to Treatment Discontinuations
ParticipantsPlaceboDC-806 200 mg BIDDC-806 400 mg BIDDC-806 600 mg QDDC-806 800 mg BID
TEAEs1219202227
SAEs00001
TEASs leading to treatment discontinuations10000

Adverse events

Collected over Baseline through End of follow-up (Up to 16 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/43 (0%)0/43 (0%)5/43 (11.6%)
DC-806 200 mg BID0/44 (0%)0/44 (0%)10/44 (22.7%)
DC-806 400 mg BID0/46 (0%)0/46 (0%)6/46 (13%)
DC-806 600 mg QD0/48 (0%)0/48 (0%)15/48 (31.3%)
DC-806 800 mg BID0/47 (0%)1/47 (2.1%)10/47 (21.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboDC-806 200 mg BIDDC-806 400 mg BIDDC-806 600 mg QDDC-806 800 mg BID
Pneumonia aspirationInfections and infestations0/430/440/460/481/47
Most frequent other events
Most frequent other events
EventPlaceboDC-806 200 mg BIDDC-806 400 mg BIDDC-806 600 mg QDDC-806 800 mg BID
Upper respiratory tract infectionInfections and infestations3/437/445/464/483/47
NasopharyngitisInfections and infestations2/432/441/467/481/47
DiarrhoeaGastrointestinal disorders0/431/440/462/483/47
VomitingGastrointestinal disorders0/430/440/461/483/47
NauseaGastrointestinal disorders0/430/440/463/482/47

Baseline characteristics

All randomized participants who received at least one dose of the study drug.

Age, Continuous
Age, Continuous(years)PlaceboDC-806 200 mg BIDDC-806 400 mg BIDDC-806 600 mg QDDC-806 800 mg BIDTotal
Mean46.7 ± 14.2442.3 ± 12.6846.0 ± 12.3541.6 ± 14.2543.4 ± 13.7644.0 ± 13.51
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDC-806 200 mg BIDDC-806 400 mg BIDDC-806 600 mg QDDC-806 800 mg BIDTotal
Female111614141772
Male3328323330156
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDC-806 200 mg BIDDC-806 400 mg BIDDC-806 600 mg QDDC-806 800 mg BIDTotal
Hispanic or Latino5426421
Not Hispanic or Latino3938434041201
Unknown or Not Reported021126
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDC-806 200 mg BIDDC-806 400 mg BIDDC-806 600 mg QDDC-806 800 mg BIDTotal
American Indian or Alaska Native010001
Asian6323519
Native Hawaiian or Other Pacific Islander000000
Black or African American120317
White3536434140195
More than one race100001
Unknown or Not Reported121015
08

Study locations

56 sites
  • First OC Dermatology
    Fountain Valley, California 92708-3701, United States
  • Clinical Science Institute
    Santa Monica, California 90404-2120, United States
  • Driven Research LLC
    Coral Gables, Florida 33134-3901, United States
  • Kirsch Dermatology - Probity - PPDS
    Naples, Florida 34102-6538, United States
  • GCP Global Clinical Professionals, LLC
    Saint Petersburg, Florida 33713-8012, United States
  • ForCare Clinical Research - CenExel FCR - PPDS
    Tampa, Florida 33613-1244, United States
  • The Indiana Clinical Trials Center, PC
    Plainfield, Indiana 46168-2792, United States
  • Dermatology Specialists Research - 501 S 2nd St
    Louisville, Kentucky 40202-2862, United States
  • DICE Therapeutics Study Site
    New York, New York 10003-3314, United States
  • Dermatologists of Southwest Ohio - Probity - PPDS
    Mason, Ohio 45040-4520, United States
  • Paddington Testing Company Inc
    Philadelphia, Pennsylvania 19103-4738, United States
  • Center for Clinical Studies - Webster
    Webster, Texas 77598-4927, United States
  • Virginia Clinical Research Inc
    Norfolk, Virginia 23502-3945, United States
  • Alberta DermaSurgery Centre - Probity - PPDS
    Edmonton, Alberta T6G 1C2, Canada
  • Enverus Medical Research - Probity - PPDS
    Surrey, British Columbia V3V 0C6, Canada
  • Wiseman Dermatology Research Inc. - Probity - PPDS
    Winnipeg, Manitoba R3M 3Z4, Canada
  • CCA Medical Research - Probity - PPDS
    Ajax, Ontario L1S 7K8, Canada
  • SimcoDerm Medical and Surgical Dermatology Centre - Probity - PPDS
    Barrie, Ontario L4M 7G1, Canada
  • Dermatrials Research
    Hamilton, Ontario L8N 1Y2, Canada
  • Lynderm Research Inc. - Probity - PPDS
    Markham, Ontario L3P 1X2, Canada
  • DermEdge Research Probity - PPDS
    Mississauga, Ontario, Canada
  • DICE Therapeutics Study Site
    North York, Ontario M2M 4J5, Canada
  • Alliance Clinical Trials - Probity - PPDS
    Waterloo, Ontario N2J 1C4, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)
    Quebec, G1V 4X7, Canada
  • Fakultni nemocnice Kralovske Vinohrady - CRC - PPDS
    Praha, Praha, Hlavní Mesto 100 00, Czechia
  • CCR Prague s.r.o. - PRATIA - PPDS
    Praha, Praha, Hlavní Mesto 130 00, Czechia
  • CCR Prague s.r.o. - PRATIA - PPDS
    Praha 10, 100 00, Czechia
  • DICE Therapeutics Study Site
    Praha 5, 150 00, Czechia
  • DICE Therapeutics Study Site
    Erlangen, Bayern 91054, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt am Main, Hessen 60590, Germany
  • DICE Therapeutics Study Site
    Bonn, Nordrhein-Westfalen 53127, Germany
  • DICE Therapeutics Study Site
    Münster, Nordrhein-Westfalen 48149, Germany
  • DICE Therapeutics Study Site
    Leipzig, Sachsen 4103, Germany
  • DICE Therapeutics Study Site
    Berlin, 10117, Germany
  • ISA - Interdisciplinary Study Association GmbH
    Berlin, 10789, Germany
  • DICE Therapeutics Study Site
    Lübeck, 23538, Germany
  • DICE Therapeutics Study Site
    Tübingen, 72076, Germany
  • Allergo-Derm Bakos Kft.
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
  • DICE Therapeutics Study Site
    Kaposvár, Somogy 7400, Hungary
  • DICE Therapeutics Study Site
    Szombathely, Vas 9700, Hungary
  • Semmelweis Egyetem
    Budapest, 1085, Hungary
  • DICE Therapeutics Study Site
    Gyöngyös, 3200, Hungary
  • MedMare Bt
    Veszprém, 8200, Hungary
  • Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.p
    Wroclaw, Dolnoslaskie 50-566, Poland
  • Wro Medica
    Wroclaw, Dolnoslaskie 51-685, Poland
  • Dermoklinika-Centrum Medyczne s.c
    Lódz, Lódzkie 90-436, Poland
  • Centrum Medyczne Reuma Park NZOZ
    Warszawa, Mazowieckie 02-665, Poland
  • Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
    Rzeszów, Podkarpackie 35-055, Poland
  • ClinicMed Daniluk, Nowak Spólka Komandytowa
    Bialystok, Podlaskie 15-879, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, Slaskie 40-611, Poland
  • Laser Clinic S.C.
    Szczecin, Zachodniopomorskie 70-332, Poland
  • Hospital Universitario de Gran Canaria Doctor Negrin
    Las Palmas De Gran Canaria, 35010, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28026, Spain
  • CHUS - H. Clinico U. de Santiago
    Santiago De Compostela, 50009, Spain
  • Synexus Merseyside Clinical Research Centre
    Liverpool, Lancashire L22 0LG, United Kingdom
  • Medicines Evaluation Unit
    Manchester, M23 9QZ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Mar 2024, 10 months.

Results were first posted in Apr 2025, 1 year after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 10 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Jun 9, 2023
StartActual
May 2, 2023
Primary completionActual
Mar 25, 2024
CompletionActual
Mar 25, 2024
Results first posted
Apr 4, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05896527
Responsible party
Sponsor
First posted
Jun 9, 2023
Start date
May 2, 2023
Primary completion
Mar 25, 2024
Completion
Mar 25, 2024
Results posted
Apr 4, 2025
Last update
Apr 4, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DC-806

Start the discussion